Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

Irene Scarfò, E. Pellegrino, Elisabetta Mereu, Ivo Kwee, Elisa Bergaggio, Giulia Garaffo, Nicoletta Vitale, Manuel Caputo, Rodolfo Machiorlatti, P. Circosta, Francesco Abate, Antonella Barreca, D. Novero, Susan Mathew, Andrea Rinaldi, Enrico Tiacci, Sara Serra, Silvia Deaglio, B. Falini, Raul RabadanF. Bertoni, Giorgio Inghirami, Roberto Piva, Michela Boi, Ramona Crescenzo, Giuditta Cuccuru, Marcello Gaudiano, Elena Lasorsa, Katia Messana, Elisa Spaccarotella, F. Tabbò, M. Todaro, Alessandro Fornari, Marco Chilosi, Alberto Zamò, F. Facchetti, Silvia Lonardi, Anna Rosaria De Chiara, Franco Fulciniti, Claudio Agostinelli, Pier Paolo Piccaluga, Christiane De Wolf-Peeters, Thomas Tousseyn, Peter Van Loo, Eva Geissinger, Hans Konrad Muller-Hermelink, Andreas Rosenwald, Andras Matolcsy, Miguel A. Piris, Maria E. Rodriguez-Pinilla

Research output: Contribution to journalArticle

Abstract

Anaplastic large-cell lymphoma (ALCL) is a clinical and biological heterogeneous disease that includes systemic anaplastic lymphoma kinase (ALK)-positive and ALKnegative entities. To discover biomarkers and/or genes involved in ALK-negative ALCL pathogenesis, we applied the cancer outlier profile analysis algorithm to a gene expression profiling data set including 249 cases of T-cell non-Hodgkin lymphoma and normal T cells. Ectopic coexpression of ERBB4 and COL29A1 genes was detected in 24% of ALK-negative ALCL patients. RNA sequencing and 59 RNA ligase-mediated rapid amplification of complementary DNA ends identified 2 novel ERBB4-truncated transcripts displaying intronic transcription start sites. By luciferase assays, we defined that the expression of ERBB4-aberrant transcripts is promoted by endogenous intronic long terminal repeats. ERBB4 expression was confirmed at the protein level by western blot analysis and immunohistochemistry. Lastly, we demonstrated that ERBB4-truncated forms show oncogenic potentials and that ERBB4 pharmacologic inhibition partially controls ALCL cell growth and disease progression in an ERBB4-positive patient-derived tumorgraft model. In conclusion, we identified a new subclass of ALK-negative ALCL characterized by aberrant expression of ERBB4-truncated transcripts carrying intronic 59 untranslated regions.

Original languageEnglish
Pages (from-to)221-232
Number of pages12
JournalBlood
Volume127
Issue number2
DOIs
Publication statusPublished - Jan 14 2016

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts'. Together they form a unique fingerprint.

  • Cite this

    Scarfò, I., Pellegrino, E., Mereu, E., Kwee, I., Bergaggio, E., Garaffo, G., Vitale, N., Caputo, M., Machiorlatti, R., Circosta, P., Abate, F., Barreca, A., Novero, D., Mathew, S., Rinaldi, A., Tiacci, E., Serra, S., Deaglio, S., Falini, B., ... Rodriguez-Pinilla, M. E. (2016). Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 127(2), 221-232. https://doi.org/10.1182/blood-2014-12-614503